Robert E. Geertsma

4.3k total citations · 2 hit papers
30 papers, 3.2k citations indexed

About

Robert E. Geertsma is a scholar working on Materials Chemistry, Biomaterials and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Robert E. Geertsma has authored 30 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Materials Chemistry, 5 papers in Biomaterials and 5 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Robert E. Geertsma's work include Nanoparticles: synthesis and applications (9 papers), Nanoparticle-Based Drug Delivery (5 papers) and Biosimilars and Bioanalytical Methods (4 papers). Robert E. Geertsma is often cited by papers focused on Nanoparticles: synthesis and applications (9 papers), Nanoparticle-Based Drug Delivery (5 papers) and Biosimilars and Bioanalytical Methods (4 papers). Robert E. Geertsma collaborates with scholars based in Netherlands, Switzerland and United Kingdom. Robert E. Geertsma's co-authors include Wim H. de Jong, Adriënne J.A.M. Sips, Werner I. Hagens, Petra Krystek, Agnes G. Oomen, Evelyn H. W. Heugens, Dik van de Meent, B Roszek, Maaike van Zijverden and Willie J.G.M. Peijnenburg and has published in prestigious journals such as SHILAP Revista de lepidopterología, Biomaterials and International Journal of Molecular Sciences.

In The Last Decade

Robert E. Geertsma

29 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Particle size-dependent organ distribution of gold nanoparticles after intravenous administration

2008 1.3k citations Wim H. de Jong, Werner I. Hagens et al. Biomaterials profile →
Nano-silver – a review of available data and knowledge gaps in human and environmental risk assessment

2009 1.0k citations S. Wijnhoven, Willie J.G.M. Peijnenburg et al. Nanotoxicology profile →

Peers

Countries citing papers authored by Robert E. Geertsma

Since Specialization

Citations

This map shows the geographic impact of Robert E. Geertsma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert E. Geertsma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert E. Geertsma more than expected).

Fields of papers citing papers by Robert E. Geertsma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert E. Geertsma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert E. Geertsma. The network helps show where Robert E. Geertsma may publish in the future.

Co-authorship network of co-authors of Robert E. Geertsma

This figure shows the co-authorship network connecting the top 25 collaborators of Robert E. Geertsma. A scholar is included among the top collaborators of Robert E. Geertsma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert E. Geertsma. Robert E. Geertsma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety notices and registry outlier data measure different aspects of safety and performance of total knee implants: a comparative study of safety notices and register outliers 2024 ·Acta Orthopaedica ·(unknown), (unknown), Tom Melvin, (unknown), Anne Lübbeke, Robert E. Geertsma, Alan G. Fraser, Rob G. H. H. Nelissen, Enrico G. Caiani, Perla J. Marang‐van de Mheen	0
2	Evaluation of Adverse Effects of Resorbable Hyaluronic Acid Fillers: Determination of Macrophage Responses 2022 ·International Journal of Molecular Sciences ·Wim H. de Jong, Danyel Jennen, Peter H. J. Keizers, Hennie M. Hodemaekers, Jolanda P. Vermeulen, Frank Bakker, (unknown), Marcel van Herwijnen, Marlon J. Jetten, Jos Kleinjans, Robert E. Geertsma, Rob J. Vandebriel	6
3	Transcriptomic Analysis in Human 3D Skin Model Injected with Resorbable Hyaluronic Acid Fillers Reveals Foreign Body Response 2022 ·International Journal of Molecular Sciences ·Danyel Jennen, Marcel van Herwijnen, Marlon J. Jetten, Rob J. Vandebriel, Peter H. J. Keizers, Robert E. Geertsma, Wim H. de Jong, Jos Kleinjans	6
4	A Decision Support System for preclinical assessment of nanomaterials in medical products: the REFINE DSS 2022 ·Drug Delivery and Translational Research ·Alex Zabeo, (unknown), Lisa Pizzol, Fanny Caputo, Sven Even Borgos, Jérémie Parot, Robert E. Geertsma, (unknown), Rob J. Vandebriel, (unknown), Danail Hristozov	3
5	Regulatory safety evaluation of nanomedical products: key issues to refine 2022 ·Drug Delivery and Translational Research ·Wim H. de Jong, Robert E. Geertsma, Gerrit Borchard	19
6	Future perspectives for advancing regulatory science of nanotechnology-enabled health products 2022 ·Drug Delivery and Translational Research ·Blanka Halamoda‐Kenzaoui, Robert E. Geertsma, (unknown), Adriele Prina‐Mello, (unknown), Matthias Roesslein, Adriënne J.A.M. Sips, (unknown), Kathleen Spring, Susanne Bremer‐Hoffmann	14
7	Nonclinical regulatory immunotoxicity testing of nanomedicinal products: Proposed strategy and possible pitfalls 2020 ·Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology ·(unknown), Margriet V.D.Z. Park, (unknown), Wim H. de Jong, Jan Willem van der Laan, Henk Van Loveren, Rob J. Vandebriel, Robert E. Geertsma	16
8	Nanomedicinal products: a survey on specific toxicity and side effects 2017 ·International Journal of Nanomedicine ·Walter Brand, C.W. Noorlander, (unknown), Wim de Jong, (unknown), Margriet V.D.Z. Park, Rob J. Vandebriel, (unknown), (unknown), Robert E. Geertsma	45
9	A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirements 2016 ·International Journal of Nanomedicine ·(unknown), Margriet V.D.Z. Park, Wim de Jong, Henk Van Loveren, Rob J. Vandebriel, Robert E. Geertsma	46
10	Immunotoxicity Testing of Nanomedicinal Products: Possible Pitfalls in Endotoxin Determination 2016 ·Rivm Repository (Netherlands National Institute for Public Health and the Environment) ·(unknown), Robert E. Geertsma, Wim H. de Jong, Henk Van Loveren, Rob J. Vandebriel, Margriet V.D.Z. Park	10
11	Results of a survey among GP practices on how they manage patient safety aspects related to point-of-care testing in every day practice 2015 ·BMC Family Practice ·(unknown), Carine J.M. Doggen, (unknown), Robert Verheij, Maarten J. IJzerman, Robert E. Geertsma, Ron Kusters	9
12	Bisphenol A : Part 1. Facts and figures on human and environmental health issues and regulatory perspectives 2014 ·Rivm Repository (Netherlands National Institute for Public Health and the Environment) ·(unknown), (unknown), (unknown), (unknown), (unknown), Robert E. Geertsma, Liesbeth Geraets, (unknown), Wim Mennes, (unknown), Aldert H. Piersma, (unknown), Dick T.H.M. Sijm, (unknown), (unknown), (unknown), Marco J. Zeilmaker	2
13	Risks related to the use of eHealth technologies : An exploratory study 2013 ·American Journal of Translational Research ·Hans C. Ossebaard, (unknown), Julia E.W.C. van Gemert‐Pijnen, Robert E. Geertsma	7
14	Considerations on the EU definition of a nanomaterial: Science to support policy making 2012 ·Regulatory Toxicology and Pharmacology ·Eric A.J. Bleeker, Wim H. de Jong, Robert E. Geertsma, Monique Groenewold, Evelyn H. W. Heugens, (unknown), Dik van de Meent, (unknown), Anton Rietveld, Susan Wijnhoven, Flemming R. Cassee, Agnes G. Oomen	126
15	Interpretation and implications of the European Commission's definition on nanomaterials 2012 ·UvA-DARE (University of Amsterdam) ·Eric A.J. Bleeker, Flemming R. Cassee, Robert E. Geertsma, Wim H. de Jong, Evelyn H. W. Heugens, (unknown), Dik van de Meent, Agnes G. Oomen, (unknown), Anton Rietveld, S. Wijnhoven	3
16	Analysis of the occupational, consumer and environmental exposure to engineered nanomaterials used in 10 technology sectors 2012 ·Nanotoxicology ·Bernd Nowack, C. Brouwer, Robert E. Geertsma, Evelyn H. W. Heugens, Bryony L. Ross, Marie-Claire Toufektsian, Susan Wijnhoven, R. John Aitken	34
17	The kinetics of the tissue distribution of silver nanoparticles of different sizes 2010 ·Biomaterials ·(unknown), Agnes G. Oomen, Petra Krystek, Arianne M. Neigh, (unknown), C.W. Noorlander, J.C.H. van Eijkeren, Robert E. Geertsma, Wim H. de Jong	411
18	Nano-silver – a review of available data and knowledge gaps in human and environmental risk assessment breakdown → 2009 ·Nanotoxicology ·S. Wijnhoven, Willie J.G.M. Peijnenburg, Carla Herberts, Werner I. Hagens, Agnes G. Oomen, Evelyn H. W. Heugens, B Roszek, (unknown), Ilse Gosens, Dik van de Meent, Susan Dekkers, Wim H. de Jong, Maaike van Zijverden, Adriënne J.A.M. Sips, Robert E. Geertsma	1022
19	Particle size-dependent organ distribution of gold nanoparticles after intravenous administration breakdown → 2008 ·Biomaterials ·Wim H. de Jong, Werner I. Hagens, Petra Krystek, (unknown), Adriënne J.A.M. Sips, Robert E. Geertsma	1264
20	Medical devices manufactured from latex: European regulatory initiatives 2002 ·Methods ·Wim H. de Jong, Robert E. Geertsma, (unknown)	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact